Related Experiment Video
Updated: Mar 7, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
Primary Systemic Amiyloidosis with Bullous Lesions
Indian Journal of Dermatology, Venereology and Leprology
|February 9, 2017
Summary
Primary systemic amyloidosis with bullous lesions, a rare manifestation associated with multiple myeloma, showed encouraging response to melphalan and prednisolone therapy. The adult patient remained well over two years post-diagnosis.
Area of Science:
- Hematology
- Oncology
- Dermatology
Background:
- Primary systemic amyloidosis is a rare plasma cell disorder.
- Bullous lesions are an uncommon manifestation of systemic amyloidosis.
- Multiple myeloma is a malignant proliferation of plasma cells.
Observation:
- An adult patient presented with primary systemic amyloidosis manifesting as bullous lesions.
- The patient had concurrent multiple myeloma.
Findings:
- The patient received treatment with melphalan and prednisolone.
- A positive therapeutic response was observed.
Implications:
- This case highlights the potential for bullous lesions in systemic amyloidosis.
- Melphalan and prednisolone may be an effective treatment regimen for this rare condition.
- Long-term remission is achievable with appropriate therapy.
Related Concept Videos
Amyloid Fibrils
6.8K
6.8K
Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
Endocarditis II: Clinical Features of Infective Endocarditis
662
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
662
Nephrotic Syndrome I : Introduction
789
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
789
Pulmonary Tuberculosis III
1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Hypersensitivity Reactions: Immune-Complex Reactions
73
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
73

